Spots Global Cancer Trial Database for Rosiglitazone Maleate in Treating Patients With Oral Leukoplakia

Study Description

Brief Summary: This phase II trial is studying how well rosiglitazone works in preventing oral cancer in patients with oral leukoplakia. Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of rosiglitazone may keep cancer from forming in patients with oral leukoplakia

Detailed Description: PRIMARY OBJECTIVES: I. To determine the rate of clinical response of oral premalignant lesions (OPL) to 12 weeks of therapy with rosiglitazone (Avandia), 8 mg daily, defined as greater than or equal to 50% reduction in the measured product of perpendicular dimension of the target lesion, or improvement in the degree of dysplasia. SECONDARY OBJECTIVES: I. To determine the rate and degree of change of putative biomarkers of rosiglitazone efficacy including: COX-2, cyclin D1, Ki-67, p21/waf1, PPAR gamma, K1 cytokeratin, involucrin, transglutaminase expressions, and TUNEL. II. To estimate the correlation between DNA ploidy measurements in OPL with clinical response and or response of biomarkers to rosiglitazone therapy, and to estimate the efficacy of rosiglitazone therapy to normalize aberrant DNA ploidy in OPL. III. To thoroughly assess smoking patterns among trial participants and to examine the relationship of smoking to treatment response. IV. To assess the safety of this agent in short-term use in this population. OUTLINE: This is a multicenter, open-label, nonrandomized study. Patients receive oral rosiglitazone once daily. Treatment continues for 12 weeks in the absence of unacceptable toxicity. After completion of study treatment, patients are followed at 1 week.

Keywords

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Contact Details

Useful links and downloads for this trial